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FSD-C10, a Fasudil derivative, 
promotes neuroregeneration 
through indirect and direct 
mechanisms
Yan-Hua Li1,*, Chong Xie2,*, Yuan Zhang2, Xing Li2, Hai-fei Zhang1, Qing Wang3, Zhi Chai3, 
Bao-guo Xiao4, Rodolfo Thome2, Guang-Xian Zhang2 & Cun-gen Ma1,3
FSD-C10, a Fasudil derivative, was shown to reduce severity of experimental autoimmune 
encephalomyelitis (EAE), an animal model of multiple sclerosis (MS), through the modulation of the 
immune response and induction of neuroprotective molecules in the central nervous system (CNS). 
However, whether FSD-C10 can promote neuroregeneration remains unknown. In this study, we 
further analyzed the effect of FSD-C10 on neuroprotection and remyelination. FSD-C10-treated mice 
showed a longer, thicker and more intense MAP2 and synaptophysin positive signal in the CNS, with 
significantly fewer CD4+ T cells, macrophages and microglia. Importantly, the CNS of FSD-C10-treated 
mice showed a shift of activated macrophages/microglia from the type 1 to type 2 status, elevated 
numbers of oligodendrocyte precursor cells (OPCs) and oligodendrocytes, and increased levels of 
neurotrophic factors NT-3, GDNF and BDNF. FSD-C10-treated microglia significantly inhibited Th1/
Th17 cell differentiation and increased the number of IL-10+ CD4+ T cells, and the conditioned medium 
from FSD-C10-treated microglia promoted OPC survival and oligodendrocyte maturation. Addition of 
FSD-C10 directly promoted remyelination in a chemical-induced demyelination model on organotypic 
slice culture, in a BDNF-dependent manner. Together, these findings demonstrate that FSD-C10 
promotes neural repair through mechanisms that involved both immunomodulation and induction of 
neurotrophic factors.
Multiple sclerosis (MS) is a chronic inflammatory debilitating disease in the Central Nervous System (CNS) that 
affects over 2 million people worldwide. Oligodendrocyte death is believed to be essential in the pathogenesis of 
MS as CNS myelin is produced by oligodendrocytes, and the loss of these cells results in demyelination, axonal 
damage and severe impairment of neurological function1–5. Concurrently with inflammation and demyelinat-
ing processes, repair mechanisms are initiated in primary demyelinated lesions. Extensive remyelination can 
be observed during the early stage of MS by recruitment, proliferation and differentiation of oligodendrocyte 
precursor cells (OPC)5. However, the remyelination is reduced after successive relapses and failure of effective 
remyelination in progressive MS lesions is associated with a lack of oligodendrocyte maturation6,7 and increased 
axonal degeneration8. Therefore, stimulation of remyelination through an increase in oligodendrocyte maturation 
in the CNS lesions is critical to the functional recovery in MS6,9.
Fasudil, an inhibitor of Rho kinases (ROCK), has been shown to have beneficial effects on CNS-related disor-
ders10,11. In EAE, Fasudil reduced the severity of disease through the stimulation of an anti-inflammatory response 
and a shift of M1 towards M2 macrophage/microglia12,13. M1 microglia secrete toxic molecules that destruct 
axon-supporting myelin and oligodendrocytes, whereas M2 cells release anti-inflammatory cytokines and growth 
factors that contribute to efficient remyelination and protect neurons from damage5,14,15. Manipulating the switch 
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from M1- to M2-dominant polarization of microglia is a desirable strategy for efficient remyelination therapies. 
In addition, failure of spontaneous remyelination is also associated with a lack of sufficient amount of neuro-
trophic factors (BDNF, NT-3 and GDNF) in the CNS during inflammation16–18. In this context, our previous 
study showed that nasal administration of FSD-C10, a derivative of Fasudil with less toxic effect, effectively sup-
pressed the clinical severity of experimental autoimmune encephalomyelitis (EAE), an animal model of MS. 
This effect was associated with a upregulated Tregs19. Still, whether FSD-C10 presents a neuroregenerative and 
neuroprotective effect has yet to be elucidated.
In the present study, we found that FSD-C10 significantly promoted neurological recovery, oligodendrogene-
sis, and remyelination. The mechanisms underlying these effects relayed on immunomodulation and direct neu-
roregeneration. Our data show that FSD-C10 has a beneficial effect on EAE acting through the modulation of the 
immune response and neuroregeneration.
Results
Intranasal FSD-C10 has a neuroprotective potential in EAE. Similar to our previous study19, nasal 
administration of FSD-C10 effectively suppressed clinical severity of EAE, with reduced CNS inflammation and 
demyelination (Figure S1). Extensive CD4+ T cells and CD68+ macrophages were found in brains from untreated 
EAE mice whereas the frequency of these cells were significantly reduced in mice treated with nasal FSD-C10 
(Figure S2). In order to study the neural protection effect of FSD-C10, we treated MOG35–55-immunized mice 
with FSD-C10 (2.5 mg/kg/d). Treatment regimen started from day 3 p.i. until day 27 p.i. At the end of treatment, 
mice were euthanized and the CNS tissue was collected and analyzed for the expression of microtubule-associ-
ated protein 2 (MAP2), which is specifically expressed in dendrites and plays a key role in dendritic outgrowth, 
branching and synaptogenesis20–22. Our data show that FSD-C10 increased MAP2 expression and improved 
MAP2 positive dendritic morphology in prefrontal cortex and hippocampus compared to tissue from untreated 
EAE mice (Fig. 1a). Similar results were also observed in spinal cord tissues (data not shown). We further exam-
ined the synaptic structure in brain and the spinal cord by analyzing the expression of synaptophysin, a protein 
found in presynaptic vesicles. This parameter allows a general analysis of spinal cord circuit integrity23,24. The 
synaptophysin positive staining in the cortex of brain and the grey matter of spinal cord of FSD-C10-treated 
mice was significantly higher than in the control mice (Fig. 1b). These results indicate that FSD-C10 performed a 
neuropreservation in the CNS of EAE mice.
Characterization of proliferative cells in the CNS of FSD-C10-treated mice. To study the mecha-
nism underlying the neuroprotective effect of FSD-C10 in EAE, we first explored and characterized cell prolifer-
ation in the CNS after treatment. Mice received 3 i.p. injections of BrdU at days 25–27 post immunization (p.i.) 
and were euthanized at 28 days p.i. Analysis of coronal brain sections showed that, while the BrdU+ proliferative 
cells were mainly concentrated in perivascular space in tissue from untreated mice, these cells were extensively 
detected in the whole brain parenchyma of FSD-C10-treated EAE mice (Fig. 2a).
We then analyzed the proliferative status of different cell types in the CNS after FSD-C10 treatment. In 
ddH2O-treated EAE mice, 30–40% of immune cells, e.g., CD4+ T cells and CD68+/CD11b+ microglia/mac-
rophages, were BrdU+, while the percentages of BrdU+ cells were significantly decreased by FSD-C10 treatment. 
In contrast, only low numbers of BrdU+ were colocalized with GFAP+ (astrocytes), NG2+ (OPCs) and GalC+ 
(mature oligodendrocytes) in ddH2O-treated EAE mice, and FSD-C10 treatment largely increased the propor-
tions of BrdU+/NG2+ and GalC+ cells (Fig. 2b). Thus, FSD-C10 treatment effectively stimulated the proliferation 
of OPC/oligodendrocyte lineage cells, but suppressed proliferation of immune cells.
Elevated numbers of OPCs and oligodendroglia in FSD-C10-treated mice. To evaluate the effects 
of FSD-C10 on OPC recruitment and oligodendrocyte maturation, immunohistofluorescence was carried out on 
brain section with antibodies to NG2 and GalC, as markers of OPCs and oligodendrocytes, respectively. A low 
number of NG2+ cells was observed in brain of EAE control mice, and a significantly increased number of these 
cells was observed in brain of FSD-C10-treated EAE mice (Fig. 3a and b). Similarly, about a 2-fold increase of 
GalC+ oligodendrocytes in the brain of FSD-C10-treated EAE mice was seen compared to those in the untreated 
mice (Fig. 3a and b). These results were further confirmed by analysis of total protein (Fig. 3c). In contrast, 
administration of FSD-C10 in naïve mice increased the number of OPCs, but not oligodendrocytes (Fig. d,e), 
indicating that FSD-C10 affects OPC lineage cells in the physiological condition, without disturbing the regula-
tion of mature myelinating cells in vivo.
Intranasal FSD-C10 stimulated the production of neurotrophic factors. It was shown that induc-
tion of neurotrophins, including NT-3, GDNF, and BDNF, plays an important role in neurogenesis, remyelina-
tion, and brain repair16,25,26. We therefore determined if FSD-C10 treatment induced these neurotrophic factors. 
Our data show that while low numbers of cells producing these neurotrophic factors appeared in the brain of 
ddH2O-treated EAE mice, significantly increased numbers were observed in the brain of FSD-C10-treated EAE 
mice (Fig. 4a and b). Similarly, total protein analysis confirmed that a strong up-regulation of these neurotrophic 
factors was found in brain of FSD-C10-treated mice compared with EAE mice (Fig. 4c). These results indicate a 
stimulatory effect of FSD-C10 in the production of neurotrophic factors in vivo.
Intranasal FSD-C10 shifted activated microglia from M1 to M2 status. Given the important roles 
of different microglia/macrophages in CNS myelination, we then determined the functional states of microglia 
after FSD-C10 treatment. In normal brain, few ramified microglia (resting microglia) can be detected, while fully 
ramified microglia (activated microglia) are numerous in middle-injured brain; elongated microglia (triangles, 
phagocytic microglia) became rod cells, and probably fuse to form cell clusters in severe-injured brain27. In our 
experiment, numerous hyper-ramified and elongated microglia with large cell body were detected in brain of 
www.nature.com/scientificreports/
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ddH2O treated EAE, indicating activated microglia. In contrast, microglia in FSD-C10-treated mice showed in a 
thin branched form (Fig. 5a and b).
Functionally, microglia can have different states, including the inflammatory and neurotoxic M1 and 
anti-inflammatory and neuroprotective M2 phenotypes28. Our results showed that, compared with control mice, 
FSD-C10-treated mice exhibited substantially reduced numbers of CD11b+ microglia/macrophages expressing 
the M1 markers iNOS and CD16/32, while numbers of these cells expressing the M2 markers IL-10 and CD206 
were significantly increased (Fig. 5c and d). FSD-C10 inhibited the protein expression of iNOS while enhanced 
the levels of Arg-1 (Fig. 5e). Similarly, levels of M1 cytokines IL-1β , IL-6 and TNF-α were significantly suppressed 
while levels of IL-10 were upregulated after FSD-C10 treatment (Fig. 5f). These results indicate that intranasal 
administration of FSD-C10 blocked the microglia activation and switched these cells from a M1 to M2 phe-
notype. While FSD-C10 treatment in naïve mice increased Arg-1 expression in microglia, it did not affect the 
expression of iNOS and CD16/32, IL-10 and CD206 (Figure S3).
Figure 1. Intranasal FSD-C10 protects neuritis and synapses from damage in EAE. EAE was induced in 
C57BL/6 mice by immunization with MOG35–55/CFA. Mice received FSD-C10 or ddH2O by intranasal pathway 
beginning on day 3 p.i. until day 27 p.i. Brain and lumbar sections of spinal cord were harvested at day 28 p.i. 
and immunostained with MAP2 and synaptophysin. (a) MAP2 expression in the cortex (areas 1, 2 and 3)  
and hippocampal region (area 4) of brain. (b) Representative microphotographs and quantitative analysis 
for synaptophysin expression in the cortex of brain and the grey matter of spinal cord. Quantitative analyses 
represent mean ± SEM (n = 7 each group). ***P < 0.001. One representative of three experiments is shown.
www.nature.com/scientificreports/
4Scientific RepoRts | 7:41227 | DOI: 10.1038/srep41227
FSD-C10 treatment inhibited Th1 and Th17 cells in EAE mice. We then explored whether intranasal 
administration of FSD-C10 could suppress the development of Th1 and Th17 cells. MOG35–55-immunized mice 
Figure 2. FSD-C10 stimulates the proliferation of OPCs and oligodendrocytes while suppresses 
proliferation of immune cells. Mice from each group received three i.p. injections of BrdU (sigma) on days 
25–27 p.i. and brains were harvested from mice described in Fig. 1. (a) Proliferating cells were identified by 
a mouse anti-BrdU antibody. (b) Immunostaining of BrdU (red) and cell-specific markers (green) including 
CD4, CD68, CD11b, NG2 and GalC were performed. Representative microphotographs of double positive 
cells for BrdU and different cell types were shown, and percentages of these double positive cells in each cell 
type were analyzed. Data represent mean ± SEM (n = 7 each group). ***P < 0.001. One representative of three 
experiments is shown.
www.nature.com/scientificreports/
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received ddH2O or FSD-C10 starting from day 3 p.i., their splenocytes obtained on 15 p.i., and treated with or 
without MOG35–55 (25 μ g/ml) for 72 h. As shown in Fig. 6a, splenocytes of FSD-C10-treated EAE mice showed a 
lower production of IL-17, TNF-α , IFN-γ and a higher production of IL-10 than those of the PBS-treated group. 
In addition, FSD-C10 treatment also reduced MOG-induced T cell proliferation in the presence or absence of 
MOG (Fig. 6b).
FSD-C10 shifted M1 to M2 phenotype in vitro. To test whether FSD-C10 treatment can directly induce 
a shift of M1 microglia towards a M2 phenotype, BV-2 microglia were firstly polarized to M1 by exposure to 
lipopolysaccharide (LPS), and then were treated with FSD-C10. The polarization was examined by immunoflu-
orescence. Results showed that LPS stimulated high expression levels of M1 markers iNOS, CD16/32 and IL-12, 
but low levels of M2 markers CD206, IL-10 and Arg-1. FSD-C10 treatment significantly inhibited the expression 
of all M1 markers, but enhanced those M2 markers (Fig. 7). These results indicate a direct effect of FSD-C10 in 
the shift to the M2 phenotype in microglia.
FSD-C10-treated microglia have a reduced ability to prime autoreactive T cells in vitro. We 
then determined the direct effect of FSD-C10 on Th1/Th17 cells in purified CD4+ T cells, and showed that add-
ing FSD-C10 in vitro significantly inhibited Th1/Th17 cell differentiation (Fig. 8). However, whether FSD-C10 
can inhibit the capacity of microglia in priming effector T cell response remains unclear. To answer this ques-
tion, we first determined the effect of FSD-C10-treated microglia on MOG-reactive T cell proliferation. While 
LPS-stimulated microglia promoted T cell proliferative responses, this capacity was inhibited when microglia 
were treated with FSD-C10 (Fig. 9a, P < 0.01). In contrast, microglia without LPS stimulation did not affect T cell 
proliferation (Fig. 9a).
Figure 3. FSD-C10 increased the numbers of OPCs and oligodendrocytes. EAE (a,b,c) or naïve mice (d,e) 
received FSD-C10 or ddH2O by intranasal pathway. Brains were harvested from mice described in Fig. 1. 
Immunohistofluorescence of OPCs (NG2+) and oligodendrocytes (GalC+) within brains were examined. 
Representative microphotographs (a,d) and quantitative analyses for NG2+ and GalC+ cells from ddH2O-
treated and FSD-C10-treated EAE mice (b,e), as well as representative Western blot photos and their 
quantitative analysis (c) were shown. Data represent mean ± SEM (n = 7 each group for brain section staining, 
and n = 4 each group for Western blot). *P < 0.05, ***P < 0.001. One representative of three experiments is 
shown.
www.nature.com/scientificreports/
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Next, we examined whether polarization of the BV-2 microglia mediated by FSD-C10 could affect the pop-
ulation and function of the encephalomyelitic T cells. FSD-C10-treated BV-2 microglia were co-cultured with 
MOG-reactive T cells. As shown in Fig. 9b, FSD-C10-treated microglia following LPS maturation induced CD4+ 
IL-10+ T cells, whereas the percentages of MOG-reactive Th1 (CD4+ IFN-γ +) and Th17 (CD4+ IL-17+) cells 
were reduced. Consistent with the FACS data, ELISA assays confirmed that FSD-C10-treated BV-2 microglia 
inhibited IFN-γ , IL-17 and TNF-α production by T cells and induced them to produce IL-10, compared with the 
PBS-treated BV-2 microglia (Fig. 9c, P < 0.05–0.01). These results indicate that FSD-C10-treated microglia can 
convert the function of MOG-reactive T cells from pro-inflammatory to an anti-inflammatory one.
Figure 4. FSD-C10 stimulated the production of GDNF, NT-3 and BDNF in EAE. Brains were harvested 
from mice described in Fig. 1, and sections were immunostained with NT-3, GDNF and BDNF antibodies. 
Representative microphotographs (a) and their quantitative analyses (b) were shown. (c) Expression of these 
neurotrophic factors in brain tissues was also determined by Western blot and quantitatively analyzed. Data 
represent mean ± SEM (n = 7 each group for brain section staining, and n = 4 each group for Western blot). 
*P < 0.05, **P < 0.01, ***P < 0.001. One representative of three experiments is shown.
www.nature.com/scientificreports/
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LPS/FSD-C10-stimulated microglia cells produce factors that promote oligodendrocyte 
survival and maturation. We further explored the function of FSD-C10-treated microglia on OPC/oligo-
dendrocytes. OPCs were incubated with conditioned media (CM) obtained from cultures where microglia cells 
were treated with PBS (M0), LPS (M1), or LPS/FSD-C10 (M2) as described above. After 24 h of incubation with 
CM, OPCs were stained with the Live/dead cell imaging kit to assess cell viability. The percentages of leaky OPCs 
were significantly lower in cells cultured with the M2-CM than those with M1-CM. The M1-CM also markedly 
induced OPC death, however, the CM from PBS- and LPS/FSD-C10-stimulated microglia exhibited a signifi-
cantly lower death rate than the LPS treatment group (Fig. 10a). These results indicate that, in contrast to M1-CM, 
conditioned media from FSD-C10-treated microglia cells has no toxic effect over OPC.
We also studied the effect of different CMs on OPC maturation. After culturing OPCs with CM for 7 days, 
these cells were stained with MBP, a marker of oligodendrocytes. Although all 3 groups of OPCs expressed MBP, 
M2-CM-treated group had elevated multipolar branches, with a significant increase in arborization (Fig. 10b). 
Taken together, the addition of M2-CM not only promoted the OPC survival but also increased the arborization/
maturation of oligodendrocytes.
FSD-C10 directly promotes remyelination in vitro in a BDNF-dependent manner. To examine 
whether FSD-C10 can directly promote remyelination, a LPC-induced demyelination model in organotypic slice 
culture was conducted. In this experimental approach, demyelination is achieved after incubation of cultures with 
Figure 5. Intranasal FSD-C10 shifted inflammatory microglia into anti-inflammatory microglia. Brains 
were harvested from mice described in Fig. 1. (a) Brains were immunostained with CD11b antibody for 
analyzing the functional states and morphological diversity of microglia. FSD-C10 treatment reduced the 
numbers of fully ramified and triangle microglia (activated microglia). The single microglia area (polygon) 
was quantitatively analyzed by Image-pro plus 6.0 software in (b). (c) Expression of M1 markers (CD16/32 and 
iNOS) and M2 markers (CD206 and IL-10) in CD11b+ cells was determined by immunohistochemistry and 
(d) double positive cells were quantitatively analyzed. (e) Expression of iNOS and Arg-1 was also measured 
by Western blot. (f) Brains were homogenized on ice, and equal amounts of protein (10 mg) were measured 
by ELISA for cytokine production. Quantitative analyses represent mean ± SEM (n = 7 each group for brain 
section staining, and n = 4 each group for Western blot and ELISA). *P < 0.05, **P < 0.01, ***P < 0.001. One 
representative of three experiments is shown.
www.nature.com/scientificreports/
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LPC for 18 h. Treatment with LPC leads to a decreased expression of MBP in organotypic cultures. When these 
demyelinated slices were treated with FSD-C10 for 14 days, MBP expression was significantly enhanced compared 
with the PBS-treated slices, suggesting a significant promotion in remyelination by FSD-C10 treatment (Fig. 11).
Given that FSD-C10 stimulated the production of the neurotrophic factors NT-3, GDNF and BDNF in vivo 
(Fig. 4), we aimed to evaluate whether these proteins played a role in FSD-C10-induced remyelination. For that 
matter, demyelinated organotypic cultures were treated with FSD-C10 in the presence of neutralizing antibod-
ies against these factors. Our results showed that FSD-C10-induced remyelination was dramatically blocked by 
anti-BDNF antibodies (Fig. 11). Blockage of GDNF or NT-3 did not revert the effect of FSD-C10 (data not shown). 
Similarly, NF-H expression (neurons) was also largely reduced when anti-BDNF antibodies were added (Fig. 11). 
These results indicate that FSD-C10 can directly induce remyelination through a BDNF-dependent pathway.
Discussion
In this paper we defined some of the mechanisms of FSD-C10-induced EAE amelioration. We found that 
FSD-C10 stimulates neurogrowth and regeneration, shifts macrophage/microglia activation profile and promotes 
remyelination. Inhibition of Rho associated kinase (ROCK) has been shown to promote OPC differentiation and 
myelin formation29–32. We have recently found that nasal administration of FSD-C10, a novel and efficient ROCK 
inhibitor, suppressed the activity and expression of ROCK, alleviated disease severity and CNS inflammation of 
EAE mice, and preserved myelin sheath19,33. Our data showed a higher proliferation rate of OPCs and mature 
oligodendrocytes in the CNS of FSD-C10-treated mice, which confirms the protective effect of FSD-C10 on CNS 
myelination in vivo. In a series of in vitro experiments, FSD-C10 treatment induced type 2 macrophages/micro-
glia and the condition media of these cells protected OPCs from inflammation-induced death and promoted the 
maturation of these cells into oligodendrocytes. Further, addition of FSD-C10 into LPC-induced demyelination 
cultures effectively promoted remyelination in a BDNF-dependent manner.
MS/EAE is initiated through the activation of encephalitogenic myelin-responsive CD4+ T cells, which invade 
the CNS1,2. Together with lymphocyte infiltration, resident microglia are activated and present self-antigens to 
lymphocytes. A large proportion of circulating monocytes infiltrate the CNS as well. Monocytes/Macrophages 
and microglia are the ultimate effector cells in neuroinflammation, leading to the destruction of the myelin sheath 
and oligodendrocyte death1,2. Microglia cells play a pivotal role in the pathogeny of MS and EAE34. In EAE, acti-
vated microglia cells release inflammatory mediators, which lead to neurotoxic consequences. The existence of 
activated microglia is the most prominent feature of chronic neuroinflammation or neurodegenerative disease35. 
Our data show that FSD-C10 treatment significantly reduced the numbers of these immune cells in the CNS. 
Their proliferation in the disease foci was also significantly inhibited following treatment. These results indicate 
that FSD-C10 can alleviate EAE through a reduction in either the recruitment of peripheral immune cells as well 
as their proliferation in the CNS. We also found that FSD-C10 kept microglia in a thin branched form or possibly 
reverted the reactive microglia back to the resting state. In addition, intranasal FSD-C10 treatment significantly 
decreased microglia proliferation and their IL-1β and TNF-α expression. As a result, the cytotoxic outcome of 
these pathologic mediators on neural cells was significantly diminished.
In CNS, microglia undergo M1 or M2 polarization in response to different environmental stimuli36. For 
instance, while M1 microglia are typically found in of MS lesions and their frequency directly correlates with the 
extent of axonal damage, M2-polarized microglia contributes to regenerative response in the CNS37. Importantly, 
M2 microglia are lacking in chronic lesion of EAE5. Blockage of M2 profile in microglia has been shown to con-
tribute to impaired remyelination38. Therefore, it is reasonable to speculate that stimulating the M2-polarized 
phenotype of microglia would confer protection from inflammation-induced neurodegeneration and demy-
elination. Our results show a clear M2 phenotype of macrophage/microglia after nasal FSD-C10 treatment. 
Interestingly, FSD-C10-treated microglia effectively induced IL-10-producing, but inhibited IFN-γ /IL-17 pro-
ducing T cells, and conditioned media from M2 cultures increased the survival rate of OPCs and arborization/
Figure 6. Immunomodulatory effects of intranasal FSD-C10 in the periphery. Splenocytes from each 
group of EAE mice (n = 3) were harvested on day 12 p.i., (a) In vivo inhibition of pro-inflammatory cytokines. 
Splenocytes were cultured at 5 × 106 cells/ml and stimulated with MOG35–55 for 3 days. Cytokine production 
in supernatants was analyzed by ELISA. (b) Splenocytes were cultured at 2 × 106 cells/ml in 100 μ l/well and 
stimulated with or without MOG35–55 for 3 days and labeled with BrdU for cell proliferation assay by an ELISA 
reader following the manufacturer’s instructions (Abcam) (n = 8 each group). **P < 0.01, comparisons between 
ddH2O-treated animals and FSD-C10-treated groups. One representative of three experiments is shown.
www.nature.com/scientificreports/
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maturation of oligodendrocytes. Our observations suggest that FSD-C10 treatment induces M2 microglia, which 
have the capacity to enhance OPC survival and their maturation into oligodendrocytes.
It has been shown that loss of trophic support for oligodendrocytes and neurons leads to the failure of spon-
taneous remyelination and neural recovery in MS/EAE39. A treatment that has capacity to induce the production 
of neurotrophic factors in the disease foci would be greatly beneficial. Indeed, overexpression of NT-3 in neural 
stem cells reduces CNS inflammation and neurological deficits in ongoing EAE through the stimulation of prolif-
eration and differentiation of neural stem cells into oligodendrocytes and neurons culminating in remyelination 
and neuronal repopulation16. Local release of NT-3 also reduces astrogliosis, a main cause of MS plaque forma-
tion40,41. GDNF, a member of the TGF-β superfamily42, promotes survival and differentiation of dopaminergic 
and motor neurons43,44, selectively enhances regrowth of damaged axons45, and induces myelin formation18,46. 
BDNF is well-known to promote neuronal survival and axonal growth47,48. BDNF also stimulates oligodendrocyte 
Figure 7. FSD-C10 shifted BV-2 microglia from M1 to M2 by immunostaining in vitro. BV-2 microglia were 
stimulated with PBS or LPS (0.5 μ g/ml) in the absence or presence of FSD-C10 (15 μ g/ml) for 24 h. Cells were 
stained with M1 microglia markers CD16/32, iNOS as well as M2 markers CD206, Arg-1. IL-12 and IL-10 were 
checked with ELISA. Representative photographs and quantitative analyses (mean ± SEM; n = 5 each group) 
from immunostaining and ELISA are shown. Results are expressed as number of immunostaining positive cells 
per view field and pg/ml. Groups designated by the same letter are not significantly different, while those with 
different letters (a,b,c) are significantly different (p < 0.05). One representative of three experiments is shown.
www.nature.com/scientificreports/
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differentiation and maturation49,50, and protect the myelinated axons51,52. Although FSD-C10 treatment upregu-
lated the production of NT-3, GDNF and BDNF, we found that blockage of BDNF abolished the beneficial effect 
of FSD-C10. Thus, BDNF plays an important role in FSD-C10-induced remyelination.
Our study showed that FSD-C10 is an efficient therapeutic drug for EAE. By inhibiting the migration and 
expansion of peripheral immune cells in the CNS, shifting macrophages/microglia from M1 to an M2 phenotype, 
and enhancing the production of neurotrophic factors, FSD-C10 demonstrated to exert several immune and 
non-immune beneficial effects in the course of neuroinflammation. Ultimately, FSD-C10 promoted remyelina-
tion and neuroprotection. Together, these findings demonstrate that FSD-C10 promotes neural repair in CNS 
autoimmunity through mechanisms involved both immunomodulation and induction of neurotrophic factors.
Materials and Methods
Mice. Female C57BL/6 mice (10–12 weeks and 18–20 g) were purchased from Vital River Laboratory Animal 
Technology Co. Ltd. (Beijing, China). All animal experiments were conducted in adherence with the International 
Council for Laboratory Animal Science guidelines. The study was approved by the Council for Laboratory and 
Ethics Committee of Shanxi Datong University, Datong, China. All mice were housed under pathogen-free con-
ditions and kept in a reversed 12:12-h light/dark cycle in a temperature-controlled room (25 ± 2 °C) for one week 
prior to experimental manipulation.
Induction of chronic EAE. EAE were induced as described previously19. Mice were subcutane-
ously immunized with 300 μ g mouse myelin oligodendrocyte glycoprotein 35–55 peptide (MOG35–55, 
MEVGWYRSPFSRVVHLYRNGK) in Freund’s complete adjuvant (Sigma-Aldrich, St. Louis, MO, USA) supple-
mented with 3 mg/ml of Tuberculosis H37Ra (BD Difco, NJ, USA). In addition, 750 ng Pertussis toxin (Enzo Life 
Sciences, NY, USA) was injected intraperitoneally on days 0 and 2 p.i. MOG35–55 was produced in an automatic 
synthesizer (CL. Bio-Scientific., Xi’an, China). Purity of the peptide was > 95% as determined by HPLC.
Administration of Fasudil derivative FSD-C10. MOG35–55 immunized mice were divided into 2 groups 
(n = 12 each group), and normal mice were also divided into 2 groups (n = 6 each group); all were treated with 
either FSD-C10 (FSD-C10-treated) or ddH2O (ddH2O-treated control). FSD-C10 is a Fasudil derivative that is 
easily soluble in ethanol, and suitably water-soluble. FSD-C10 (from Tianjin Chase Sun Pharmaceutical Co., Ltd, 
Tian’jin, China) was dissolved in sterile ddH2O. For intranasal administration, mice were slightly anesthetized 
with diethylether, and then received 10 μ l/each nostril (2.5 mg/kg/day) of FSD-C10 at the opening of the nostrils 
on day 3 until day 27 p.i., allowing the animal to sniff the solution into the upper nasal cavity. Mice that received 
the same volume of ddH2O nasally served as untreated control.
Figure 8. FSD-C10 modulated Th1 and Th17 cell differentiation. For differentiation of Th1 and Th17 cells, 
purified CD4+ T cells of normal female C57BL/6 mice (8 wks) were stimulated with anti-CD3 and anti-CD28 
for 3 days under (a,b) Th1 polarization conditions (IL-12 and anti-IL-4) and (c,d) Th17 polarization conditions 
(TGF-β 1, IL-6, IL-1β , anti-IL-4 and anti-IFN-γ ) in the presence or absence of FSD-C10. Percentages of IFN-γ +  
CD4+ Th1 cells and IL-17+ CD4+ Th17 cells were determined by flow cytometry. Data represent mean ± SEM 
(n = 5 each group). ***P < 0.001. One representative of three experiments is shown.
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Cell proliferation. To study in vivo cell proliferation, mice received daily i.p. injections of BrdU (50 mg/
kg) (Sigma) on days 25 until 27 p.i, and brain tissues were harvested at day 28 p.i. Proliferating cells were iden-
tified by using a mouse anti-BrdU antibody (1:500, Thermo Fisher Scientific, Waltham MA, USA) following 
experimental procedure recommended by the manufacturer. Briefly, brain sections were pretreated 10 min in 
Figure 9. FSD-C10-treated microglia induce the conversion of MOG-reactive T cells in vitro. CD4+ T 
cells from EAE mice were labeled with CFSE and co-cultured with BV-2 microglia that were stimulated with 
or without LPS and treated with PBS- or FSD-C10 at an estimated ratio of 10:1, in the presence of MOG35–55 
(25 μ g/ml) for 72 h. (a) Percentage of proliferating cells was determined through the measurement of CFSE 
dilution using flow cytometry. Data represent mean ± SEM (n = 5 each group). (b) IFN-γ , IL-10, and IL-17 
secretion was analyzed using flow cytometry. Data represent mean ± SEM (n = 5 each group). (c) The levels 
of IFN-γ , IL-10, IL-17, and TNF-α in culture supernatants were detected using ELISA kits. Data represent 
mean ± SEM (n = 8 each group). *P < 0.05, **P < 0.01, ***P < 0.001. One representative of three experiments is 
shown.
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paraformaldehyde (PFA) 4%, rinsed in PBS, and incubated 30 min in a solution of 2 N HCL. Slides were rinsed 
twice in PBS, and sections were incubated 10 min at 37 °C with the 0.1% trypsin. Slides were rinsed three times in 
PBS and then stained with anti- BrdU antibody.
Tissue processing. Mice underwent intracardiac perfusion under deep anesthesia with saline and 4% PFA 
solution in PBS. Brains were removed, and incubated overnight in sucrose solution 10%, 20%, and 30% respec-
tively at 4 °C. 10 μ m coronal brain sections were collected on poly-lys-coated slides by leica cryotome (Leica, 
Rueil-Malmaison, France). Brain slices were cut (− 0.82 to − 2.54 mm posterior to bregma based on the paxinos 
atlas) for 170 sequential sections.
Immunohistochemistry. Brain slides were air-dried, permeabilized, and blocked for 1 h and primary 
antibody applied overnight at 4 °C in a humid chamber. Fluorescently-conjugated secondary antibodies were 
applied for 2 h at room temperature in a humid chamber. Antibodies used to detect M1 microglia are as follows: 
mouse anti-iNOS (Enzo Life Sciences), rat anti-CD16/32 (BD Pharmingen, NJ, USA), anti-TNFα (Peprotech, 
NJ, USA), and IL-12 (Peprotech). Antibodies used to detect M2 markers are as follows: goat anti-Arginase-1 
(anti-Arg-1, eBioscience, San Diego, CA, USA), IL-10 (Abcam, Camb, UK), CD206 (eBioscience). Antibodies 
against microglia/macrophage markers include rat anti-CD68 (Serotec, Kidlington, UK), CD4 (BD Pharmingen), 
CD11b (eBioscience). Oligodendrocyte, OPC neuron were detected by anti-NG2 (Promega, Madison, WI, USA), 
and GalC (Promega), anti-microtubule associated protein-2 (anti-MAP2, Millipore, Billericay, MA, UK) and 
anti-synaptophysin (Abcam). Other antibodies include rabbit anti-GFAP (Millipore), anti-NT-3 (Abcam), 
anti-GDNF (Novus Biologicals, CO, USA, 1:1000), anti-BDNF (Abcam). As a negative control, additional sec-
tions were treated similarly, but the primary antibodies were omitted. Results were visualized under fluorescent 
microscopy by Image-Pro Plus software or confocal laser scanning microscope (CLSM, Olympus, Tokyo, Japan) 
Figure 10. The CM from LPS/FSD-C10 stimulated microglia promoted OPC survival and oligodendrocyte 
maturation. OPCs were generated from brain of neonatal mice and cultured with conditioned media (CM) 
from microglia treated with PBS (M0), LPS (M1), or LPS+ FSD-C10 (M2) for 24 hrs. (a) OPCs were stained 
using Live/Dead staining kit as given in the material and methods section, and representative images of viable 
cells, dead cells, and leaky cells were shown. These cells were then counted and quantified under fluorescent 
microscopy by Image-Pro Plus software in a blinded fashion. (b) We added M0-CM, M1-CM and M2-CM to 
the OPC differentiation media in a 1:1 ratio and the OPCs were cultured for 7 days. Cells were then stained 
by anti-MBP antibody. Representative images and quantification of length of cell branches were shown, and 
measurements were done with Image-Pro Plus software. Data in this figure represent mean ± SEM (n = 5 each 
group). **P < 0.01; **P < 0.001. One representative of three experiments is shown.
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Figure 11. FSD-C10 directly promoted the formation of myelin sheath. Postnatal day 5 (P5) mouse pups 
were sacrificed and consecutive slices (350 μ m) were cut from the cerebellums. Three slices in each 6-well 
insert plate were cultured in 1 ml medium. LPC was added into cerebellum slice cultures for 18 hrs to induce 
demyelination and then slices were cultured with 15 μ g/ml FSD-C10 or PBS for 14 days, with or without 
antibodies to CNTF, NT-3 and BDNF. Slices were then stained with anti-MBP and anti-NF-H. Results 
were visualized by confocal microscopy and MBP and NF-H expression was analyzed by ImageJ software. 
Quantitative analyses represent mean ± SEM (n = 5 each group). Groups designated by the same letter are 
not significantly different, while those with different letters (a, b) are significantly different (p < 0.05). One 
representative of three experiments is shown.
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by FV-1200 software in a blinded fashion. Quantification was performed on three coronal sections per mouse, 
and six mice per group were analyzed.
Western blot analysis. The brains were homogenized on ice with a Ultrasonic crusher (HD3000, Wiggens, 
Beijing, China) in ice-cold lysis buffer (1 × PBS, 1% Nonidet P-40, 0.5% sodium deoxycholate, and 0.1% SDS, 
RIPA) supplemented with protease inhibitors PMSF. Lysates were centrifuged at 10,000 × g for 20 min at 4 °C for 
two times, and the supernatants were collected. Protein concentrations were determined by a Bradford protein 
assay. Equal amounts of protein (30 μ g) were separated by SDS-PAGE, and transferred onto a polyvinylidene 
fluoride filter (PVDF) membrane (Millipore). Membranes were blocked with 5% non-fat milk, and incubated at 
4 °C overnight with anti-NG2, anti-GalC, anti-GDNF, anti-NT-3, anti-BDNF, anti-iNOS, anti-Arginase-1 and 
anti-β -actin (Cell signaling, Davers, MA, USA). Bands were visualized by HRP-conjugated secondary antibodies 
(Thermo Scientific, MA, USA) and chemiluminescence (ECL) kit under ECL system (Millipore).
Cytokine measurement by ELISA. Levels of IL-1β , IL-6, TNF-α , IL-12, and IL-10 were measured by 
sandwich ELISA kits (Peprotech or R&D Systems, Minneapolis, MN) in accordance to manufacturer’s instruc-
tions. Determinations were performed in 3 independent experiments.
Splenocyte proliferation and cytokine measurement ex vivo. Splenocytes were isolated from 
ddH2O-treated and FSD-C10-treated EAE mice on day 12 p.i., and cultured with or without 25 μ g/ml MOG35–55 
peptide for 3 days. Cell proliferation was determined by BrdU-incorporation test using BrdU Cell Proliferation 
ELISA Kit (Abcam). Supernatants from splenocytes were collected at 72 h to measure concentration of IFN-γ , 
IL-17, TNF-α , and IL-10 using ELISA kits (R&D System, Minneapolis, MN).
Microglia polarization. The BV2 immortalized microglial cell line was obtained from ShenKe Biological 
Technolology CO., Ltd., Shanghai, PR China, and cultured in Dulbecco′ s modified Eagle medium (DMEM; 
Gibco, Waltham MA, USA) supplemented with 10% fetal bovine serum (FBS; Gibco), 100 U/ml penicillin, and 
100 μ g/ml streptomycin (Gibco) at 37 °C in a humidified cell incubator with a 95%/5% (v/v) mixture of air and 
CO2. BV2 cells were allowed to attach to the culture dish for 2 h. Later, cells were either left untreated or treated 
overnight with lipopolysaccharide (LPS, Sigma-Aldrich, St. Louis, MO, USA, 500 ng/ml), FSD-C10 (15 μ g/ml) or 
LPS plus FSD-C10. Conditioned media was collected and stored at − 20 °C. Cells were acquired for immunos-
taining analyses.
Th1/Th17 cell polarization of CD4+ T cells in vitro. Differentiation of Th1 and Th17 cells was induced 
in vitro following previously described protocols53. Briefly, single-cell suspensions derived from spleen of normal 
female C57BL/6 mice (6–8 week) were purified by negative selection with a mouse CD4+ T Cell Isolation Kit II 
(Miltenyi Biotec). Purified naïve CD4+ T cells were cultured with soluble anti-CD3e (5 μ g/ml) and anti-CD28 
(2 μ g/ml) under their respective polarizing conditions. IL-12 (5 ng/ml) was added to induce differentiation into 
Th1 cells. TGF-β 1 (2 ng/ml), IL-6 (20 ng/ml), IL-1β (10 ng/ml), anti-IL-4 (10 μ g/ml), and anti-IFN-γ (10 μ g/ml) 
were added in Th17 polarizing conditions. FSD-C10 at 15 μ g/ml was also added to define its direct effect on Th1/
Th17 cell differentiation, and cultures without FSD-C10 served as control. Cells were collected 3 days later for 
flow cytometric analysis.
Co-culture of microglia and MOG-reactive T cells. Splenocytes were harvested from the spleen of EAE 
mice on day 8 p.i., and CD4+ T cells were purified using anti-mouse CD4 magnetic beads (Miltenyi Biotech, 
Auburn, CA, USA). These cells were then labeled with carboxyfluorescein diacetate succinimidyl ester (CFSE) for 
20 min and washed for co-culture assay. The number of proliferating cells was determined through CFSE dilution 
with flow cytometry.
BV-2 microglia were cultured in the presence or absence of LPS (500 ng/ml) and/or FSD-C10 (15 μ g/ml) for 
24 h, washed, and then co-cultured with MOG-reactive CD4+ T cells prepared as described above at an estimated 
ratio of 1:10 (microglia: T cells) in the presence of MOG35–55 (25 μ g/ml) for 72 h. Culture supernatants were col-
lected to analyze cytokine production, and the cells obtained for flow cytometric analysis.
Flow cytometry. Splenocytes were stimulated with 50 ng/ml PMA and 500 ng/ml ionomycin in the presence 
of GolgiPlug for 4 h. Cells were surface-stained with mAb against CD4. Cells were then washed, fixed, and per-
meabilized with Fix & Perm Medium (Invitrogen), and intracellular cytokines were stained with Abs against IL17, 
and IFN-γ , or IL10 (BD Biosciences). Flow cytometric analysis was performed on FACSAria (BD Biosciences, San 
Jose, CA) and data were analyzed with FlowJo software (Treestar, Ashland, OR).
Immunocytochemistry staining. BV-2 cells were plated in 24 wells plates with coverslips. Cells were fixed 
with 4% PFA solution, washed in PBS for three times. Antibodies used to detect M1 microglia are as follows: 
anti-iNOS, anti-CD16/32. Antibodies used to detect M2 markers are as follows: anti-Arg-1, CD206. Results were 
visualized by confocal microscopy (FV1200; Olympus, Japan).
OPC culture and conditioned medium treatment. OPCs were isolated from CNS tissue of mice using 
magnetic isolation beads according to manufacturer’s instruction (CD140a (PDGFRa), Miltenyi Biotec, Cologne, 
Germany) and cultivated as follows. 2 × 104/ml OPCs were plated in 24-well plates with 1 ml DMEM/F12 con-
taining 10 ng/ml PDGF AA, 20 ng/ml b-FGF, 2% N2, 2% B27, 1% p/o29,54. OPCs were treated with microglia 
media as conditioned media (CM) added in a 1:1 ratio to OPC culture media. After culturing for 24 h, viability 
of OPCs was assessed by using the Live/Dead® Cell Imaging kit (Invitrogen, Cal, USA) in accordance with the 
protocol provided by the manufacturer. Twenty to 60 images were made from each sample and in each image the 
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cells were counted. Cells with a green fluorescent cytoplasm and a dark nucleus were counted as “viable cells”, 
while cells with only a red nucleus were counted as “dead cells”. Cells that had a red nucleus with green cytoplasm, 
and were consequently in an intermediate state between viable and dead, were denoted as “leaky cells”. The sum 
number of viable cells, dead cells and leaky cells were defined as “total cells”55–57. Results were expressed as num-
ber of different type of cell per view field. Data are presented as mean ± SEM. To study the effect of conditioned 
media (CM) on OPC differentiation, we cultured OPCs in DMEM/DF12 medium containing 2% N2, 2% B27, 
40 ng/ml triiodothyronine and 10 ng/ml ciliary neurotrophic factor (CNTF). We added CM to the differentiation 
medium in a 1:1 ratio and the OPCs were cultured for 7 days. Cells were then stained by anti-myelin basic protein 
(MBP, Abcam) antibody.
FSD-C10 treatment of LPC-induced demyelination in cerebellum slice cultures. Postnatal day 5 
(P5) mice pups were killed, and the cerebellums were removed and dissected in the dissection medium contain-
ing 50% HBSS, 50% Opti-MEM, following previously described protocol58,59. Consecutive slices (350 μ m) were 
cut from the cerebellums using a tissue chopper. We cultured 3 slices in each 6-well insert plate (Millipore) with 
1 ml medium composed of 25% heat-inactivated horse serum, 25% HBSS, 50% Opti-MEM. Demyelination was 
performed by adding 10 mg/ml lysophosphatidylcholine (LPC, Sigma-Aldrich) in the media on day 10. After 
culturing 12 h of adding LPC, slices were washed and transplanted to new inserts, and 15 μ g/ml FSD-C10 or PBS 
was added to the culture media. To study the effect of neurotrophins on remyelination, neutralizing antibodies 
to GDNF, NT-3 and BDNF (Abcam, USA) were also added to the media. Slices were stained with anti-MBP 
and anti-NF-H on day 24 after culturing. Results were visualized by confocal microscopy (LSM 510; Zeiss, Jena, 
Germany).
Statistical analysis. GraphPad Prism software was used for statistical analysis. Data are presented as 
mean ± SEM. Experiments were analyzed by Student’s t-tests, and P-values were considered statistically signifi-
cant when P < 0.05.
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